VENLAFAXINE

Venlafaxine Adverse Events Reported to the FDA Over Time

How are Venlafaxine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Venlafaxine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Venlafaxine is flagged as the suspect drug causing the adverse event.

Most Common Venlafaxine Adverse Events Reported to the FDA

What are the most common Venlafaxine adverse events reported to the FDA?

Drug Withdrawal Syndrome	3249 (2.98%)
Dizziness	1767 (1.62%)
Nausea	1719 (1.57%)
Anxiety	1649 (1.51%)
Depression	1624 (1.49%)
Suicidal Ideation	1492 (1.37%)
Headache	1491 (1.37%)
Drug Ineffective	1479 (1.35%)
Feeling Abnormal	1350 (1.24%)
Completed Suicide	1258 (1.15%)
Insomnia	1128 (1.03%)
	Show More
Condition Aggravated	1079 (.99%)
Paraesthesia	1069 (.98%)
Drug Interaction	1017 (.93%)
Drug Exposure During Pregnancy	1003 (.92%)
Tremor	951 (.87%)
Malaise	938 (.86%)
Fatigue	921 (.84%)
Suicide Attempt	883 (.81%)
Vomiting	829 (.76%)
Hyperhidrosis	803 (.74%)
Confusional State	799 (.73%)
Agitation	785 (.72%)
Somnolence	740 (.68%)
Convulsion	710 (.65%)
Crying	690 (.63%)
Diarrhoea	679 (.62%)
Weight Increased	647 (.59%)
Fall	645 (.59%)
Intentional Overdose	609 (.56%)
Asthenia	597 (.55%)
Withdrawal Syndrome	596 (.55%)
Serotonin Syndrome	584 (.53%)
Irritability	530 (.49%)
Hypertension	525 (.48%)
Pain	512 (.47%)
Aggression	510 (.47%)
Overdose	495 (.45%)
Disturbance In Attention	483 (.44%)
Anger	461 (.42%)
Dyspnoea	460 (.42%)
Panic Attack	451 (.41%)
Blood Pressure Increased	450 (.41%)
Cardiac Arrest	450 (.41%)
Drug Dependence	437 (.4%)
Tinnitus	431 (.39%)
Vertigo	425 (.39%)
Constipation	397 (.36%)
Tachycardia	397 (.36%)
Drug Effect Decreased	388 (.36%)
Unevaluable Event	380 (.35%)
Loss Of Consciousness	373 (.34%)
Weight Decreased	368 (.34%)
Nightmare	363 (.33%)
Nervousness	355 (.33%)
Restlessness	352 (.32%)
Amnesia	341 (.31%)
Drug Toxicity	336 (.31%)
Hypotension	330 (.3%)
Memory Impairment	324 (.3%)
Gait Disturbance	323 (.3%)
Product Substitution Issue	319 (.29%)
Abnormal Dreams	315 (.29%)
Abnormal Behaviour	313 (.29%)
Emotional Disorder	312 (.29%)
Disorientation	311 (.28%)
Hyponatraemia	307 (.28%)
Activities Of Daily Living Impaired	305 (.28%)
Vision Blurred	297 (.27%)
Balance Disorder	296 (.27%)
Palpitations	293 (.27%)
Thinking Abnormal	286 (.26%)
Pyrexia	283 (.26%)
Intentional Drug Misuse	274 (.25%)
Heart Rate Increased	272 (.25%)
Depressed Mood	271 (.25%)
Respiratory Arrest	269 (.25%)
Hypoaesthesia	266 (.24%)
Hallucination	260 (.24%)
Death	259 (.24%)
Mania	259 (.24%)
Mental Disorder	255 (.23%)
Dry Mouth	254 (.23%)
Muscle Spasms	253 (.23%)
Decreased Appetite	247 (.23%)
Impaired Work Ability	246 (.23%)
Chills	233 (.21%)
Chest Pain	231 (.21%)
Speech Disorder	221 (.2%)
Atrial Septal Defect	220 (.2%)
Sleep Disorder	220 (.2%)
Multiple Drug Overdose Intentional	219 (.2%)
Influenza Like Illness	218 (.2%)
Abdominal Pain	217 (.2%)
Coma	217 (.2%)
Mood Swings	217 (.2%)
Cardio-respiratory Arrest	214 (.2%)
Arthralgia	212 (.19%)
Myalgia	211 (.19%)
Multiple Drug Overdose	210 (.19%)
Muscle Twitching	210 (.19%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Venlafaxine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Venlafaxine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Venlafaxine

What are the most common Venlafaxine adverse events reported to the FDA?

Neurological	8615 (7.89%)
Therapeutic And Nontherapeutic Effe...	6697 (6.13%)
Anxiety Disorders	3988 (3.65%)
Suicidal And Self-injurious Behavio...	3973 (3.64%)
Gastrointestinal Signs	3797 (3.48%)
Medication Errors	2453 (2.25%)
Depressed Mood Disorders	2332 (2.14%)
Sleep Disorders	2284 (2.09%)
Cardiac Arrhythmias	2215 (2.03%)
Movement Disorders	2149 (1.97%)
Respiratory	2058 (1.88%)
	Show More
Psychiatric	1951 (1.79%)
Mood Disorders	1784 (1.63%)
Headaches	1749 (1.6%)
Injuries	1735 (1.59%)
Chemical Injury And Poisoning	1674 (1.53%)
Mental Impairment	1478 (1.35%)
Cardiac And Vascular Investigations	1442 (1.32%)
Muscle	1411 (1.29%)
Gastrointestinal Motility And Defec...	1381 (1.26%)
Epidermal And Dermal Conditions	1313 (1.2%)
Personality Disorders	1300 (1.19%)
Deliria	1257 (1.15%)
Physical Examination Topics	1233 (1.13%)
Lifestyle Issues	1169 (1.07%)
Skin Appendage Conditions	1157 (1.06%)
Seizures	1148 (1.05%)
Disturbances In Thinking	1129 (1.03%)
Cardiac And Vascular Disorders Cong...	1095 (1%)
Infections - Pathogen Unspecified	1074 (.98%)
Neuromuscular	941 (.86%)
Inner Ear And Viiith Cranial Nerve	897 (.82%)
Vision	767 (.7%)
Musculoskeletal And Connective Tiss...	761 (.7%)
Electrolyte And Fluid Balance Condi...	748 (.69%)
Appetite And General Nutritional	730 (.67%)
Hepatic And Hepatobiliary	712 (.65%)
Hepatobiliary	678 (.62%)
Decreased And Nonspecific Blood Pre...	641 (.59%)
Hematology Investigations	587 (.54%)
Product Quality Issues	581 (.53%)
Vascular Hypertensive	576 (.53%)
Cardiac Disorder Signs	573 (.52%)
Renal Disorders	540 (.49%)
Manic And Bipolar Mood Disorders	535 (.49%)
Toxicology And Therapeutic Drug Mon...	528 (.48%)
Urinary Tract Signs	508 (.47%)
Changes In Physical Activity	480 (.44%)
Lower Respiratory Tract Disorders	456 (.42%)
Myocardial	456 (.42%)
Joint	454 (.42%)
Central Nervous System Vascular	445 (.41%)
Cardiac Valve	442 (.4%)
Psychiatric And Behavioural Symptom...	439 (.4%)
Coronary Artery	409 (.37%)
Vascular	389 (.36%)
Body Temperature Conditions	375 (.34%)
Lipid Analyses	370 (.34%)
Ocular Neuromuscular	366 (.34%)
Bone And Joint Injuries	365 (.33%)
Neonatal And Perinatal Conditions	357 (.33%)
Fatal Outcomes	345 (.32%)
Metabolic, Nutritional And Blood Ga...	335 (.31%)
Allergic Conditions	331 (.3%)
Gastrointestinal Hemorrhages	317 (.29%)
Salivary Gland Conditions	317 (.29%)
Heart Failures	288 (.26%)
White Blood Cell	286 (.26%)
Enzyme	282 (.26%)
Viral Infectious	270 (.25%)
Sexual Function And Fertility	269 (.25%)
Anemias Nonhemolytic And Marrow Dep...	267 (.24%)
Sexual Dysfunctions, Disturbances A...	262 (.24%)
Glucose Metabolism Disorders	254 (.23%)
Musculoskeletal And Connective Tiss...	248 (.23%)
Upper Respiratory Tract Disorders	248 (.23%)
Water, Electrolyte And Mineral	247 (.23%)
Schizophrenia And Other Psychotic	236 (.22%)
Neonatal Respiratory	229 (.21%)
Sleep Disturbances	228 (.21%)
Pulmonary Vascular	224 (.21%)
Eye	219 (.2%)
Bacterial Infectious	214 (.2%)
Abortions And Stillbirth	205 (.19%)
Gastrointestinal Conditions	205 (.19%)
Endocrine Investigations	195 (.18%)
Renal And Urinary Tract Investigati...	189 (.17%)
Platelet	184 (.17%)
Oral Soft Tissue Conditions	172 (.16%)
Bone Disorders	171 (.16%)
Obstetric And Gynecological Therape...	170 (.16%)
Musculoskeletal And Connective Tiss...	166 (.15%)
Angiedema And Urticaria	165 (.15%)
Legal Issues	164 (.15%)
Hearing	159 (.15%)
Ocular Sensory Symptoms	155 (.14%)
Economic And Housing Issues	152 (.14%)
Bronchial Disorders	150 (.14%)
Therapeutic Procedures And Supporti...	148 (.14%)
Cranial Nerve Disorders	146 (.13%)
Thyroid Gland	137 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Venlafaxine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Venlafaxine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.